http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Presentation+of+PAS-004+Data+to+European+Society+for+Medical+Oncology+%28ESMO%29+Congress+2026/26791928.html <p><strong><em>-- </em></strong>Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October 23, 2026</p> <p><strong><em>--</em></strong> Full abstract will be published on ESMO website per Congress’ standard embargo schedule</p> <p>MIAMI, July 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=4DlBVgIoPGJ8njuHbMHUHOT_DH73tJGRfXprhcuIznCc6x_6lTHMw1_LCiPb2RQdULIXpnS9aCWHVOECyLzFrAFYIUfCwYP7OjM4FDBJ7AE=" rel="nofollow" target="_blank"><u>Pasithea Therapeutics Corp.</u></a> (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Presentation+of+PAS-004+Data+to+European+Society+for+Medical+Oncology+%28ESMO%29+Congress+2026/26791928.html Tue, 21 Jul 2026 07:00:00 -0400 KTTA http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Presentation+of+PAS-004+Data+to+European+Society+for+Medical+Oncology+%28ESMO%29+Congress+2026/26791928.html <p><strong><em>-- </em></strong>Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October 23, 2026</p> <p><strong><em>--</em></strong> Full abstract will be published on ESMO website per Congress’ standard embargo schedule</p> <p>MIAMI, July 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=4DlBVgIoPGJ8njuHbMHUHOT_DH73tJGRfXprhcuIznCc6x_6lTHMw1_LCiPb2RQdULIXpnS9aCWHVOECyLzFrAFYIUfCwYP7OjM4FDBJ7AE=" rel="nofollow" target="_blank"><u>Pasithea Therapeutics Corp.</u></a> (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Presentation+of+PAS-004+Data+to+European+Society+for+Medical+Oncology+%28ESMO%29+Congress+2026/26791928.html Tue, 21 Jul 2026 07:00:00 -0400 KTTA http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26+Vision+Summit/26744148.html <p><strong>July 16 in Boston, management will engage with investors and industry participants at the healthcare-focused event covering neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology, and neuroimmunology</strong></p><p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank"><u>Pasithea Therapeutics Corp.</u></a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26+Vision+Summit/26744148.html Wed, 08 Jul 2026 07:02:00 -0400 KTTA http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26+Vision+Summit/26744148.html <p><strong>July 16 in Boston, management will engage with investors and industry participants at the healthcare-focused event covering neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology, and neuroimmunology</strong></p><p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank"><u>Pasithea Therapeutics Corp.</u></a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26+Vision+Summit/26744148.html Wed, 08 Jul 2026 07:02:00 -0400 KTTA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Coastlands+Capital+LP/26722648.html si-local-file:///var/storage/secattach/20260701/26722648.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Coastlands+Capital+LP/26722648.html Wed, 01 Jul 2026 20:02:00 -0400 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Coastlands+Capital+LP/26722648.html si-local-file:///var/storage/secattach/20260701/26722648.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Coastlands+Capital+LP/26722648.html Wed, 01 Jul 2026 20:02:00 -0400 KTTA O.47854289 http://www.streetinsider.com/FDA/Pasithea+reports+Phase+1+interim+data+for+cancer+drug+PAS-004/26709384.html <p>Pasithea Therapeutics Corp. (Nasdaq: KTTA) released interim Phase 1 data for its oral MEK inhibitor PAS-004, showing no dose-limiting toxicities and no treatment-related discontinuations among 34 enrolled patients with advanced solid tumors, according to a company press release.</p> <p>Data collected through May 22, 2026 showed all treatment-related adverse events were Grade 1 or 2. Rash occurred in 12% of patients and diarrhea in 6% across all doses. No retinal or cardiac toxicity events were recorded. Ten patients remained on study for more than 90 days, with two patients exceeding 365 days.</p> <p>Among 12 patients with BRAF V600E mutations who had previously progressed http://www.streetinsider.com/FDA/Pasithea+reports+Phase+1+interim+data+for+cancer+drug+PAS-004/26709384.html Tue, 30 Jun 2026 07:00:26 -0400 KTTA http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Positive+Interim+Phase+1+Advanced+Cancer+Study+Data+Demonstrating+Long-Term+Safety+and+Tolerability%2C+and+Durable+Clinical+Activity+in+MEKBRAF-Pretreated+Patients%2C+plus/26709345.html <p style="padding-left:0pt;"><strong><em>-- </em></strong><strong>Favorable Safety Profile Supports Long-Term Chronic Dosing:</strong> PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of rash and gastrointestinal toxicities</p> <p style="padding-left:0pt;"><strong>-- Protocol Amendment Extends Dose Escalation to Higher Levels: </strong>Continued dose escalation using tablet formulation to explore 18mg, 24mg, 30mg, 40mg, and up to 52mg dose levels to further characterize safety, pharmacokinetics (PK), and early efficacy signals at higher doses</p> <p style="padding-left:0pt;"><strong>--</strong> <strong>Potential Best-in-Class MEK Inhibitor Profile Emerging</strong>: Interim PK and safety data at pharmacologically active doses support PAS-004 http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Positive+Interim+Phase+1+Advanced+Cancer+Study+Data+Demonstrating+Long-Term+Safety+and+Tolerability%2C+and+Durable+Clinical+Activity+in+MEKBRAF-Pretreated+Patients%2C+plus/26709345.html Tue, 30 Jun 2026 07:00:00 -0400 KTTA http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Positive+Interim+Phase+1+Advanced+Cancer+Study+Data+Demonstrating+Long-Term+Safety+and+Tolerability%2C+and+Durable+Clinical+Activity+in+MEKBRAF-Pretreated+Patients%2C+plus/26709345.html <p style="padding-left:0pt;"><strong><em>-- </em></strong><strong>Favorable Safety Profile Supports Long-Term Chronic Dosing:</strong> PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of rash and gastrointestinal toxicities</p> <p style="padding-left:0pt;"><strong>-- Protocol Amendment Extends Dose Escalation to Higher Levels: </strong>Continued dose escalation using tablet formulation to explore 18mg, 24mg, 30mg, 40mg, and up to 52mg dose levels to further characterize safety, pharmacokinetics (PK), and early efficacy signals at higher doses</p> <p style="padding-left:0pt;"><strong>--</strong> <strong>Potential Best-in-Class MEK Inhibitor Profile Emerging</strong>: Interim PK and safety data at pharmacologically active doses support PAS-004 http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Positive+Interim+Phase+1+Advanced+Cancer+Study+Data+Demonstrating+Long-Term+Safety+and+Tolerability%2C+and+Durable+Clinical+Activity+in+MEKBRAF-Pretreated+Patients%2C+plus/26709345.html Tue, 30 Jun 2026 07:00:00 -0400 KTTA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Stonepine+Capital+Management%2C+LLC/26680741.html si-local-file:///var/storage/secattach/20260623/26680741.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Stonepine+Capital+Management%2C+LLC/26680741.html Tue, 23 Jun 2026 17:41:00 -0400 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Stonepine+Capital+Management%2C+LLC/26680741.html si-local-file:///var/storage/secattach/20260623/26680741.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Stonepine+Capital+Management%2C+LLC/26680741.html Tue, 23 Jun 2026 17:41:00 -0400 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pasithea+Therapeutics+++++For%3A+Jun+17++Filed+by%3A+Coastlands+Capital+LP/26671343.html si-local-file:///var/storage/secattach/20260622/26671343.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pasithea+Therapeutics+++++For%3A+Jun+17++Filed+by%3A+Coastlands+Capital+LP/26671343.html Mon, 22 Jun 2026 10:31:00 -0400 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pasithea+Therapeutics+++++For%3A+Jun+17++Filed+by%3A+Coastlands+Capital+LP/26671343.html si-local-file:///var/storage/secattach/20260622/26671343.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pasithea+Therapeutics+++++For%3A+Jun+17++Filed+by%3A+Coastlands+Capital+LP/26671343.html Mon, 22 Jun 2026 10:31:00 -0400 KTTA O.47854289 http://www.streetinsider.com/FDA/PASITHEA+amends+NF1+trial+protocol%2C+adds+higher+doses+and+longer+treatment/26650233.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) has amended the clinical study protocol for its Phase 1/1b trial of PAS-004, a macrocyclic MEK inhibitor, in patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, according to a press release.</p> <p>The amendments to the dose-escalation portion of the study (Part A) allow enrollment of additional participants at two higher dose levels of 24mg and 32mg, the ability to backfill completed dose cohorts of 4mg, 8mg, 12mg, and 18mg with up to two participants each, and the evaluation of intermediate dose levels.</p> <p>Patients in Part A may now remain on treatment for up to 18 months, up http://www.streetinsider.com/FDA/PASITHEA+amends+NF1+trial+protocol%2C+adds+higher+doses+and+longer+treatment/26650233.html Tue, 16 Jun 2026 07:00:22 -0400 KTTA http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Amendments+to+Clinical+Study+Protocol+for+Phase+11B+NF1+Clinical+Trial/26650180.html <p align="left"><em>-- Remains on track to release interim NF1 data update in Q4 2026 --</em><br /><em>-- Additional dose levels and longer treatment period added --</em></p> <p>MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gzRjXN9G0fVxavm0wSMNpm1jQC0hcjnyvZbdeOr3nuXJwuPJwJrrbx6XLYtnEXSzC2UfvxTh68UTLeo4eLS32noBxfF8Iwt4YjW-6IXzEyU=" rel="nofollow" target="_blank"><u>Pasithea Therapeutics Corp.</u></a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced it has amended the clinical study protocol for the Phase 1/1b trial of PAS-004 in neurofibromatosis type 1 (NF1) patients with symptomatic inoperable, incompletely resected, or recurrent plexiform neurofibroma (PN). The amendments include an update to the dose escalation part of http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Amendments+to+Clinical+Study+Protocol+for+Phase+11B+NF1+Clinical+Trial/26650180.html Tue, 16 Jun 2026 07:00:00 -0400 KTTA